NOVO.TO Novo Nordisk CDR (CAD Hedged)
- Market cap
- -
- P/E
- 10.2x
- P/B
- 1.74x
- ROE
- -
- Dividend yield
- 2.42%
- Fundamental score
- -
Is NOVO.TO undervalued?
Graham numberThe Graham number of Novo Nordisk CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novo Nordisk CDR (CAD Hedged) fundamental analysis
No fundamental analysis for Novo Nordisk CDR (CAD Hedged) yet.
Novo Nordisk CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novo Nordisk CDR (CAD Hedged)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segm…
Full company profileFinancial statements of Novo Nordisk CDR (CAD Hedged) are not available yet.
Novo Nordisk CDR (CAD Hedged) dividends
Novo Nordisk CDR (CAD Hedged) has not paid dividends in the last 1 fiscal years.
Who owns Novo Nordisk CDR (CAD Hedged)
Ownership data of Novo Nordisk CDR (CAD Hedged) is not available yet.
Novo Nordisk CDR (CAD Hedged) company profile
- Company name
- Novo Nordisk CDR (CAD Hedged)
- Ticker
- NOVO.TO
- Exchange
- Toronto Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 78,554
- Address
- Website
- -
About Novo Nordisk CDR (CAD Hedged)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.